Some case–control and large follow-up studies have shown an association of higher circulating or cerebrospinal fluid level of adiponectin with increased risk of AD (Une et al. 2011; van Himbergen et al. 2012; Khemka et al. 2014), but other authors found no difference in adiponectin level between patients with AD, VaD, MCI and healthy controls (Warren et al. 2012; Bigalke et al. 2011; Dukic et al. 2016). Here, ADIPOQ is linked to Alzheimer disease.